thenewsfacts.com
  • Home
  • Latest News
  • Trending News
  • Entertainment
  • Technology
  • Sports
  • Business
  • Health
thenewsfacts.comthenewsfacts.com
Font ResizerAa
Search
  • Home
  • Latest News
  • Trending News
  • Entertainment
  • Technology
  • Sports
  • Business
  • Health
Follow US
© thenewsfacts : All Rights Reserved.

Home » iNCOVACC Fast Facts: World’s first Intranasal vaccine approved by India

COVID Vaccines

iNCOVACC Fast Facts: World’s first Intranasal vaccine approved by India

TheNewsFacts
Last updated: November 29, 2022 6:49 pm
TheNewsFacts
Share
iNCOVACC Fast Facts: World’s first Intranasal vaccine approved by India
SHARE

Bharat Biotech iNCOVACC®️ (BBV154), has received approval from the Central Drugs Standard Control Organisation (CDSCO) under Restricted Use in Emergency Situation for ages 18 and above, in India, for heterologous booster doses.

In heterologous boosting, a person administered a different vaccine from the one that was used for the primary dose series.

Key Facts about iNCOVACC Vaccine

  • iNCOVACC®️ is the world’s first Intranasal vaccine for COVID to receive approval for the primary 2-dose schedule, and heterologous booster dose.
  • iNCOVACC®️ had earlier received approval under Restricted Use in Emergency Situation for ages 18 and above for primary 2-dose schedule. Phase III trials were conducted for safety, immunogenicity in ~3100 subjects, at 14 trial sites across India.
  • Heterologous booster dose studies were conducted for safety and immunogenicity in ~875 subjects, with BBV154 intranasal vaccine administered post 2 doses of the two commonly administered COVID-19 vaccines. The trials were conducted at 9 trial sites across India.

What is iNCOVACC?

iNCOVACC®️ is a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilized SARS-CoV-2 spike protein. This vaccine candidate was evaluated in phases I, II and III clinical trials with successful results. iNCOVACC®️ has been specifically formulated to allow intranasal delivery through nasal drops. The nasal delivery system has been designed and developed to be cost-effective in low- and middle-income countries.

iNCOVACC®️ was developed in partnership with Washington University, St. Louis, which had designed and developed the recombinant adenoviral vectored construct and evaluated in preclinical studies for efficacy. Product development related to preclinical safety evaluation, large-scale manufacturing scale up, formulation and delivery device development, including human clinical trials were conducted by Bharat Biotech.

Product development and clinical trials were funded in part by the Government of India, through the Department of Biotechnology’s, COVID Suraksha Program.

Dr. Krishna Ella, Chairman & Managing Director, Bharat Biotech, said, “iNCOVACC®️, is an intranasal vaccine for the primary 2-dose schedule, and heterologous booster dose. This is a great achievement for us and the global scientific community to enable nasal administration of COVID vaccines. Despite the lack of demand for COVID vaccines, we continued product development in intranasal vaccines to ensure that we are well-prepared with platform technologies for future infectious diseases. We thank the Ministry of Health, CDSCO, Dept of Biotechnology, Govt of India, Technology Development Board, and Washington University, St. Louis, for their support and guidance. iNCOVACC®️ has been designed for efficient distribution, easy and pain-free administration. We have also initiated development of variant-specific vaccines for COVID for future preparedness.”

Clinical trials were conducted to evaluate iNCOVACC®️ as a primary dose schedule, and as heterologous booster dose for subjects who have previously received two doses of the two commonly administered COVID vaccines in India.

Immunogenicity was evaluated through serum neutralizing antibodies by PRNT assays and serum IgG’s through ELISA’s. To evaluate vaccine, taken through the intranasal route, IgA’s were evaluated by ELISA in serum and saliva. Evaluation was also carried out for ability iNCOVACC®️ to elicit long-term memory T and B cell responses against the ancestral and omicron variants.

Dr. Rajesh S. Gokhale, Secretary, DBT, and Chairperson, BIRAC, lauded the efforts of the scientific community and said, “DBT is fostering biotech enterprises & innovation ecosystem and strategically strengthening Indian bioeconomy. DBT, along with BIRAC, is dedicated to the development of effective and safe COVID-19 vaccines under Mission COVID Suraksha. The DCGI’s approval of Bharat Biotech’s intranasal vaccine iNCOVACC®️ (BBV154) to be used as a heterologous booster dose against currently available COVID-19 vaccines is a moment of great pride for our country. This move will further strengthen our collective fight against the pandemic and broaden vaccine coverage.”

“We are excited by the expansion of the EUA for iNCOVACC®️ as a booster, which enables this intranasal vaccine to be used by many more people, and hopefully curtail transmission,” said Michael S. Diamond, MD, PhD, of Washington University in St. Louis, who co-developed the nasal vaccine technology with Washington University colleague David Curiel, MD, PhD. “This approval will increase the options for people to get vaccinated and protected against the SARS-CoV-2 virus during the ongoing pandemic.”

Bharat Biotech to further develop iNCOVACC Technology

Washington University licensed the vaccine technology to Bharat Biotech in 2020 for further development.

iNCOVACC®️ was evaluated to determine its impact on safety. The reactogenic events and adverse events that were documented during the trial were highly comparable to published data from other Covid-19 vaccines. Product development data will be submitted to peer reviewed journals and will be made available in the public domain.

iNCOVACC®️ has the double benefit of enabling faster development of variant-specific vaccines and easy nasal delivery that enables mass immunization to protect from emerging variants of concern. It promises to become an important tool in mass vaccinations during pandemics and endemics. With the receipt of this approval, launch dates, pricing and availability will be announced in due course of time.

iNCOVACC®️ is stable at 2-8°C for easy storage and distribution. Bharat Biotech has established large manufacturing capabilities at multiple sites across India, including Gujarat, Karnataka, Maharashtra and Telangana, with operations pan India.

TAGGED: Bharat Biotech, Bharat Biotech Vaccine, Fast Facts iNCOVACC, iNCOVACC, iNCOVACC approval, iNCOVACC Vaccine
Share This Article
Twitter Email Copy Link Print
Previous Article China's Foxconn's factory unrest may lead to serious shortage of iPhone's China’s Foxconn’s factory unrest may lead to serious shortage of iPhone’s
Next Article Vizag Tech Summit 2023 announces INR 3000 Cr Projected Investments Vizag Tech Summit 2023 announces INR 3000 Cr Projected Investments

Your Trusted Source for Accurate and Timely Updates!

We're committed to providing accurate and unbiased news as it unfolds, earning the trust of a large audience. Stay informed with our news updates on the latest events and trends, keeping you ahead of the curve.
FacebookLike
TwitterFollow
InstagramFollow

Popular Posts

Washing Clothes to Policy-Making: PM Modi Opens Up on Podcast

January 10, 2025: PM Modi’s debut on a podcast platform has become the talk of…

By TheNewsFacts

J&J Covid19 vaccine trials in India unlikely, is it true?

Johnson & Johnson is unlikely to undertake local bridging trials for its single-shot COVID-19 vaccine…

By TheNewsFacts

Greenko Chief Anil Chalamalasetty Awarded JNTU Science Doctorate for Sustainable Energy Solutions

Hyderabad, India , June 1 2023: Green Energy Innovator, Entrepreneur, and CEO & MD of…

By TheNewsFacts

You Might Also Like

Bharat Biotech HILLCHOL
Latest News

Bharat Biotech’s Oral Cholera Vaccine HILLCHOL Demonstrates Success in Phase III Clinical Studies

By TheNewsFacts
Biovet Lumpy Skin Disease Vaccine Launched
Latest News

BIOLUMPIVAXIN: New Vaccine Now Available to Protect Livestock from LSD

By NewsFacts Bureau
Bharat Biotech
Latest News

Bharat Biotech’s New Therapies Bring Hope for Cancer and Genetic Disorders

By TheNewsFacts
Sapigen Biologix Mega Vaccine Plant in Odisha
Latest News

Singapore President Impressed by Sapigen Biologix Mega Vaccine Plant in Odisha

By TheNewsFacts
thenewsfacts thenewsfacts

About US


TheNewsFacts: Brings you the interesting facts, news facts and updates from India an the world across politics, tech, entertainment, business, tending, and more. We deliver what you love to read.
Top Categories
  • Latest News
  • Trending News
  • Paris Olympics 2024
  • Sports
  • Entertainment
  • Business
  • Technology
Usefull Links
  • About The News Facts
  • Latest News
  • Privacy Policy
  • Editorial Policy
  • Disclaimer
  • Contact Us
Follow us
Facebook Twitter Instagram

© thenewsfacts. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?